Galera Therapeutics reports statistically significant results in a 223-patient phase IIb trial of GC4419 for oral mucositis in head and neck cancer December 29, 2017Vol.40 No.11
PD-1 antibody cemiplimab demonstrates 46.3% ORR in advanced cutaneous squamous cell carcinoma December 29, 2017Vol.40 No.11
Genentech’s Tecentriq and Avastin reduce the risk of disease worsening or death from RCC December 29, 2017Vol.40 No.11
Phase III study of venetoclax in combination with rituximab meets primary endpoint December 29, 2017Vol.40 No.11
Juno Therapeutics and Celgene release additional data from TRANSCEND trial December 29, 2017Vol.40 No.11
Pfizer’s talazoparib extends PFS in phase III trial in metastatic breast cancer December 29, 2017Vol.40 No.11
Conversation with The Cancer LetterFree Lefkofsky: CancerLinQ has value in ushering in an era of precision medicine December 21, 2017Vol.44 No.01By Paul Goldberg
Conversation with The Cancer LetterFree Hudis: ASCO needed collaborators to help CancerLinQ deliver faster on its mission December 21, 2017Vol.44 No.01By Paul Goldberg
Free ASCO forms collaboration with two Big Data firms to grow CancerLinQ December 21, 2017Vol.44 No.01By Paul Goldberg
